No need for a megadeal, Pfizer CEO says. We'll grow despite looming Lyrica generics

Pfizer CEO Ian Read contends that the company's pipeline is strong enough to fuel growth, even after its second-best-selling product, Lyrica, goes off the patent cliff. In other words, don't look for a "transformative" deal.